Long-term follow-up of hepatitis B treatments
Part of Digestive system, Infections clinical trials.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old, and if you’re over 70 you should be in generally stable health
- You have had hepatitis B showing on blood tests for more than 6 months, or liver changes from hepatitis B seen on testing
- You are currently taking (or plan to start) one of these: entecavir, tenofovir disoproxil, tenofovir alafenamide, or another listed tenofovir option
- Or you are planning to take pegylated interferon (pegIFNα-2b), with or without prior hepatitis B treatment
- You agree to join the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.